Global Blood Therapeutics Stock Price

0.18 (0.27%)
Upgrade to Real-Time
Afterhours (Closed)
Volume 5,756,286
Bid Price 66.50
Ask Price 66.72
News -
Day High 66.81


52 Week Range


Day Low 66.59
Company Name Stock Ticker Symbol Market Type
Global Blood Therapeutics Inc GBT NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.18 0.27% 66.75 20:00:00
Open Price Low Price High Price Close Price Prev Close
66.67 66.59 66.81 66.75 66.57
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
40,638 5,756,286 $ 66.71 $ 384,023,068 - 21.65 - 73.02
Last Trade Time Type Quantity Stock Price Currency
19:45:10 2 $ 66.72 USD


Draw Mode:

Global Blood Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 4.50B 67.46M 65.68M $ 194.75M $ - -4.82 -13.30
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 68.77k 2.70%

more financials information »

Global Blood Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical GBT Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week47.5573.0246.571766.0914,639,27619.2040.38%
1 Month35.3373.0231.5159.804,793,14631.4288.93%
3 Months27.2373.0221.6547.702,715,19339.52145.13%
6 Months31.0073.0221.6541.881,890,67835.75115.32%
1 Year29.9373.0221.6536.431,638,61336.82123.02%
3 Years48.2887.5421.6545.651,223,33118.4738.26%
5 Years28.9087.5421.6545.571,124,35637.85130.97%

Global Blood Therapeutics Description

Global Blood Therapeutics Inc operates in the healthcare sector of the United States. It discovers and develops novel therapeutics to address blood-based disorders. GBT440, its lead drug candidate targets the underlying mechanism of red blood cell (RBC) sickling, which provides the potential to treat sickle cell disease. GBT440. an oral, once-daily therapy arrests abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. In addition, the company is engaged in other research and development activities targeted at hereditary angioedema and owns exclusively licensed rights to its portfolio of product candidates in the United States, Europe, and other major markets.

Your Recent History
Global Blo..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now